{"id":61368,"date":"2025-06-04T07:04:25","date_gmt":"2025-06-04T05:04:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/"},"modified":"2025-06-04T07:04:25","modified_gmt":"2025-06-04T05:04:25","slug":"fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/","title":{"rendered":"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only"},"content":{"rendered":"
\n

GENT, Belgium & MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD<\/a>–H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE\u00ae G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes.<\/p>\n

<\/a>
<\/a><\/p>\n

\nsTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer\u2019s and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio\u2019s growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company\u2019s leading position in advancing neuro biomarker research tools and diagnostics.<\/p>\n

\n\u201cBy adding sTREM2 to our neuro portfolio, we\u2019re enabling a more comprehensive view of neurological disease mechanisms,\u201d<\/i> said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. \u201csTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation – offering a more complete picture of the disease on a single platform.\u201c<\/i><\/p>\n

\nThe new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements.<\/p>\n

\nAbout Fujirebio<\/b><\/p>\n

\nFujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro<\/i> diagnostics (IVD) testing. It has more than 50 years\u2019 accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.<\/p>\n

\nFujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools.<\/p>\n

\nMore information can be found at www.fujirebio.com\/neuro<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nFor media:<\/b>
Public Relations Section, Public Relations\/Sustainability Dept.
\n
Phone: +81-3-6279-0884
\n
Email: pr@hugp.com<\/a><\/p>\n

\nFor investors and analysts:<\/b>
IR\/SR Dept.
\n
Phone: +81-3-6279-0926
\n
Email: ir@hugp.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GENT, Belgium & MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE\u00ae G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61368","6":"format-standard","7":"category-industry"},"yoast_head":"\nFujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GENT, Belgium & MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE\u00ae G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-04T05:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250603254214\/en\/2487199\/22\/3-1_01_FRlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only\",\"datePublished\":\"2025-06-04T05:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603254214\\\/en\\\/2487199\\\/22\\\/3-1_01_FRlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/\",\"name\":\"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603254214\\\/en\\\/2487199\\\/22\\\/3-1_01_FRlogo.jpg\",\"datePublished\":\"2025-06-04T05:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603254214\\\/en\\\/2487199\\\/22\\\/3-1_01_FRlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250603254214\\\/en\\\/2487199\\\/22\\\/3-1_01_FRlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/","og_locale":"en_US","og_type":"article","og_title":"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only - Pharma Trend","og_description":"GENT, Belgium & MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE\u00ae G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-04T05:04:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250603254214\/en\/2487199\/22\/3-1_01_FRlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only","datePublished":"2025-06-04T05:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/"},"wordCount":434,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250603254214\/en\/2487199\/22\/3-1_01_FRlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/","url":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/","name":"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250603254214\/en\/2487199\/22\/3-1_01_FRlogo.jpg","datePublished":"2025-06-04T05:04:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250603254214\/en\/2487199\/22\/3-1_01_FRlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250603254214\/en\/2487199\/22\/3-1_01_FRlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-expands-its-neuro-testing-portfolio-with-the-launch-of-the-fully-automated-lumipulse-g-strem2-assay-for-research-use-only\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse\u00ae G sTREM2 Assay for Research Use Only"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61368"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61368\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}